A multidisciplinary investigation of a polycythemia vera cancer cluster of unknown origin

International Journal of Environmental Research and Public Health

Volumn 7, Issue 3, 2010, Pages 1139-1153

  Seaman, Vincent ^a   Dearwent, Steve M ^a   Gable, Debra ^a   Lewis, Brian ^a   Metcalf, Susan ^a   Orloff, Ken ^a   Tierney, Bruce ^a   Zhu, Jane ^a   Logue, James ^b   Marchetto, David ^b   Ostroff, Stephen ^b   Hoffman, Ronald ^c   Xu, Mingjiang ^c   Carey, David ^d   Erlich, Porat ^d   Gerhard, Glenn ^d   Roda, Paul ^d   Iannuzzo, Joseph ^e   Lewis, Robert ^e   Mellow, John ^e   Mulvihill, Linda ^f   Myles, Zachary ^f   Wu, Manxia ^f   Frank, Arthur ^g   Gross Davis, Carol Ann ^g   Klotz, Judith ^g   Lynch, Adam ^g   Weissfeld, Joel ^h   Weinberg, Rona ⁱ   Cole, Henry ^j   more..

^a AGENCY FOR TOXIC SUBSTANCES AND DISEASE REGISTRY   (United States)

^b PENNSYLVANIA DEPARTMENT OF HEALTH   (United States)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^d GEISINGER HEALTH SYSTEM   (United States)

^e Pennsylvania Department of Environmental Protection   (United States)

^f CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^g DREXEL UNIVERSITY   (United States)

^h UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

ⁱ NEW YORK BLOOD CENTER   (United States)

^j Henry S Cole and Associates   (United States)

more..

Author keywords

Cancer cluster; Environmental exposure; Pennsylvania; Polycythemia vera

Indexed keywords

JANUS KINASE 2;

ARTICLE; CANCER EPIDEMIOLOGY; CANCER REGISTRY; CANCER RESEARCH; DISEASE MARKER; ENVIRONMENTAL EXPOSURE; ENVIRONMENTAL FACTOR; GENE MUTATION; GENETIC ANALYSIS; GENETIC SCREENING; GENETIC SUSCEPTIBILITY; GENOTOXICITY; HEALTH CARE FACILITY; HEALTH EDUCATION; HEMATOLOGIC MALIGNANCY; HUMAN; POLYCYTHEMIA VERA; PUBLIC HEALTH; RISK FACTOR; UNITED STATES; CLUSTER ANALYSIS; HEMATOLOGIC NEOPLASMS;

CLUSTER ANALYSIS; ENVIRONMENTAL EXPOSURE; HEMATOLOGIC NEOPLASMS; HUMANS; PENNSYLVANIA; POLYCYTHEMIA VERA;

EID: 77950874205     PISSN: None     EISSN: 16604601     Source Type: Journal    
DOI: 10.3390/ijerph7031139     Document Type: Article

References (13)

1. Pennsylvania Department of Health. Tamaqua Area Cancer Incidence Study. 1996 through 2002; Bureau of Epidemiology, Pennsylvania Department of Health: Harrisburg, PA, USA, 2005.
2. Rollison, D.E.; Howlader, N.; Smith, M.T.; Strom, S.S.; Merritt, W.D.; Ries, L.A.; Edwards, B.K.; List, A.F. Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs. Blood 2008, 112, 45-52.
3. Tefferi, A. Polycythemia vera: A comprehensive review and clinical recommendations. Mayo. Clin. Proc. 2003, 78, 174-194.
4. Kralovics, R.; Passamonti, F.; Buser, A.S.; Teo, S.; Tiedt, R.; Passweg, J.R.; Tichelli, A.; Cazzola, M.; Skoda, R.C. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N. Engl. J. Med. 2005, 352, 1779-1790.
5. Kralovics, R.; Stockton, D.; Prchal, J. Clonal hematopoiesis in familial polycythemia vera suggests the involvement of multiple mutational events in the early pathogenesis of the disease. Blood 2003, 102, 3793-3796.
6. Landgren, O.; Goldin, L.R.; Kristinsson, S.Y.; Helgadottir, E.A.; Samuelsson, J.; Bjorkholm, M. Increased risks of polycythemia vera, essential thrombocythemia, and myelofibrosis among 24,577 first-degree relatives of 11 039 patients with myeloproliferative neoplasms in Sweden. Blood 2008, 112, 2199-2204.
7. Jones, A.V.; Chase, A.; Silver, R.T.; Oscier, D.; Zoi, K.; Wang, Y.L.; Cario, H.; Pahl, H.L.; Collins, A.; Reiter, A.; Grand, F.; Cross, N.C.P. JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms. Nat. Genet. 2009, 41, 446-449.
8. Olcaydu, D.; Harutyunyan, A.; Jager, R.; Berg, T.; Gisslinger, B.; Pabinger, I.; Gisslinger, H.; Kralovics, R. A common JAK2 haplotype confers susceptibility to myeloproliferative neoplasms. Nat. Genet. 2009, 41, 450-454.
9. Kilpivaara, O.; Mukherjee, S.; Schram, A.M.; Wadleigh, M.; Mullally, A.; Ebert, B.L.; Bass, A.; Marubayashi, S.; Heguy, A.; Garcia-Manero, G.; Kantarjian, H.; Offit, K.; Stone, R.M.; Gilliland, D.G.; Klein, R.J.; Levine, R.L. A germline JAK2 SNP is associated with predisposition to the development of JAK2V617F-positive myeloproliferative neoplasms. Nat. Genet. 2009, 41, 455-459.
10. Smith, C.A.; Fan, G. The saga of JAK2 mutations and translocations in hematologic disorders: pathogenesis, diagnostic and therapeutic prospects, and revised World Health Organization diagnostic criteria for myeloproliferative neoplasms. Hum. Pathol. 2008, 39, 795-810.
11. Seaman, V.; Jumaan, A.; Yanni, E.; Lewis, B.; Neyer, J.; Roda, P.; Xu, M.; Hoffman, R. Use of molecular testing to identify a cluster of patients with polycythemia vera in eastern Pennsylvania. Cancer Epidem. Biomarker. Prev. 2009, 18, 534-540.
12. Shuga, J.; Zhang, J.; Samson, L.D.; Lodish, H.F.; Griffith, L.G. In vitro erythropoiesis from bone marrow-derived progenitors provides a physiological assay for toxic and mutagenic compounds. Proc. Nat. Acad. Sci. USA 2007, 104, 8737-8742.
13. Aldrich, T.; Sinks, T. Things to know and do about cancer clusters. Cancer Invest. 2002, 20, 810-816.